A Phase 4 interventional study of Octreotide and LAR Lanreotide in Neuroendocrine Tumors, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 218 studies in Neuroendocrine Tumors with a site in United States — 44 open to participants now, 77 under way, 10 of them phase 3. Neuroendocrine Tumors · United States.
Among the 218 studies in Neuroendocrine Tumors with a site in United States, this one is the 76th largest by enrollment of the 189 interventional ones that give a count, is one of 22 that started in 2017, is one of 5 in phase 4, and was the 116th registered.
543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.
Browse Neuroendocrine Tumors studies →44 of the 218 studies in Neuroendocrine Tumors with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Washington University School of Medicine · Sites in United States
Ages 18+
Compass Therapeutics · Sites in United States
Ages 18+
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in United States, Brazil, France and 6 more countries
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
218 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 72 · Phase 2 110 · Phase 3 18 · Phase 4 5
First in 2001; this study’s year is marked. 22 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is above the median of 41 across 387 interventional studies indexed under Neuroendocrine Tumors.
Median enrollment 36 across the 189 interventional studies, 203 across the 24 observational. Of the 125 that completed or were terminated, 70 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 218 have an industry lead sponsor. The 10 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 326 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
Memorial Sloan Kettering Cancer Center has 9 studies filed under Neuroendocrine Tumors — fewer than ten, so there is no comparison to draw.
29 of the studies in Neuroendocrine Tumors with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477576Phase 3RayzeBio, Inc.Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | 2026-12 |
| NCT04919226Phase 3ITM Solucin GmbHLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | 2027-06 |
| NCT07087054Phase 3Crinetics Pharmaceuticals Inc.Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | 2027-08 |
| NCT06881992Phase 3RezoluteA Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | 2027-09 |
| NCT05263050Fox Chase Cancer CenterTrial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 218 studies in Neuroendocrine Tumors with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day 1 or not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
*Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections
Drug: Octreotide · Drug: LAR Lanreotide · Behavioral: Questionnaires
Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
Drug: Octreotide · Drug: LAR Lanreotide · Behavioral: Questionnaires
Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
Mean Pain Scores at 3 Months
Patients will rate, on a numeric scale of 0 to 10, with 0 being No pain" to 10 being "Worst pain ever" the pain or discomfort experienced with the SSA injection.
Time frame: 3 months
| Milestone | Octreotide Then Lanreotide | Lanreotide Then Octreotide |
|---|---|---|
| Started | 26 | 25 |
| Completed | 22 | 22 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Patients will rate, on a numeric scale of 0 to 10, with 0 being No pain" to 10 being "Worst pain ever" the pain or discomfort experienced with the SSA injection.
| scores on a scale | Octreotide Then Lanreotide | Lanreotide Then Octreotide |
|---|---|---|
| Octreotide, first intervention (3 months) | 2.4 (0 to 10) | — |
| Lanreotide, second intervention (6 months) | 2.4 (0 to 10) | — |
| Lanreotide, first intervention (3 months) | — | 1.9 (0 to 10) |
| Octreotide, second intervention (6 months) | — | 1.9 (0 to 10) |
Collected over Up to 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Octreotide | 13/51 (25.5%) | 13/51 (25.5%) | 0/51 (0%) |
| Lanreotide | 8/51 (15.7%) | 8/51 (15.7%) | 0/51 (0%) |
| Event | Octreotide | Lanreotide |
|---|---|---|
| Death NOSGeneral disorders | 13/51 | 8/51 |
| Age, Continuous(years) | Octreotide Then Lanreotide | Lanreotide Then Octreotide | Total |
|---|---|---|---|
| Mean | 63 (40 to 83) | 67 (47 to 87) | 65 (40 to 87) |
| Sex: Female, Male(Participants) | Octreotide Then Lanreotide | Lanreotide Then Octreotide | Total |
|---|---|---|---|
| Female | 11 | 15 | 26 |
| Male | 15 | 10 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Octreotide Then Lanreotide | Lanreotide Then Octreotide | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 23 | 21 | 44 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Race (NIH/OMB)(Participants) | Octreotide Then Lanreotide | Lanreotide Then Octreotide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 4 | 4 |
| White | 21 | 19 | 40 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(Participants) | Octreotide Then Lanreotide | Lanreotide Then Octreotide | Total |
|---|---|---|---|
| United States | 26 | 25 | 51 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Apr 2023, 66 months.
Results were first posted in May 2025, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Octreotide
Memorial Sloan Kettering Cancer Center →